Urothelial carcinomas research and our anti-PYGB polyclonal antibody

May 2022 (Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea)

PYGB: a newly discovered IHC biomarker to pinpoint specific urothelial carcinomas and avoid misdiagnoses in routine practice.

The inverted urothelial papilloma (IUP) is a rare, non-invasive endophytic urothelial tumor of the urinary tract that accounts for 1–2% of all urothelial neoplasms.

The overlapping histology between IUP and the papillary urothelial carcinoma (PUC, with inverted growth) is a diagnostic pitfall leading to frequent misdiagnoses.

Supported by an extensive proteomic landscape data and machine learning-based analysis, this is the first study to confirm PYGB as a specific biomarker able to distinguish between IUP and PUC.

Our anti-PYGB polyclonal antibody, HPA031067 was used in IHC on FFPE tissue specimens from the Pathology Department of the Seoul National University Hospital.

The image above (from Minsun Jung, et al. 2022) shows the PYGB immunostaining in IUP vs. PUC with inverted growth.

Read more: https://lnkd.in/d5bZj-jt.